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6Abstract
In 2015 the European Commission Initiative on Breast Cancer (ECIBC) started the development 
of a voluntary European Quality Assurance scheme for Breast Cancer Services (the European 
QA scheme) through the technical and scientific coordination of the Directorate-General Joint 
Research Centre (JRC). To support the JRC in this task, a Quality Assurance Scheme Development 
Group (QASDG), consisting of independent experts, was established.
The European QA scheme’s scope (The Scope) represented the first output of the development 
process of the European QA scheme. Via a public call, stakeholders and individual citizens were 
invited to provide their feedback on The Scope. 
The call was open from 17 February to 9 March 2016 and an on-line questionnaire via the EU 
Survey platform on the ECIBC web hub was made available. The JRC received a total of 63 valid 
responses from 15 individuals (24 % of total valid responses) and 48 organisations (76 %). 
Individuals and organisations from 23 out of 28 EU Member States (82 %) contributed to this 
exercise.
During a meeting held in Varese (Italy) in March 2016,  QASDG discussed how the results of the 
call for feedback should be reflected in The Scope. Decisions taken during that meeting were 
recorded in the meeting’s minutes and The Scope was modified accordingly. The final version 
of The Scope was approved by QASDG on 16 May 2016 and was later made publicly available 
together with this report.
71 Introduction
In 2012, the Directorate-General for Health and Food Safety (DG SANTE) mandated the European 
Commission’s Joint Research Centre (JRC) to coordinate the European Commission Initiative 
on Breast Cancer (ECIBC). The ECIBC’s objectives include the development of the European 
guidelines for breast cancer screening and diagnosis (henceforth the European Breast Guidelines) 
and the development of a voluntary European Quality Assurance scheme for Breast Cancer 
Services (henceforth the European QA scheme). The European QA scheme will define a common 
set of quality and safety requirements for breast cancer services in Europe. The scheme will 
cover all relevant processes of breast cancer care. Its requirements will be defined on the basis 
of evidence-based recommendations arising from high-quality guidelines, best professional 
practices, and the relevant legislation1. Once finished, it will be piloted by a restricted list of 
breast cancer services in Europe selected via a call for expressions of interest and according to 
a set of characteristics. The piloting is being designed to test the scheme’s robustness across 
a diversity of healthcare settings. More information about the European QA scheme and the 
ECIBC is available at the ECIBC web hub2.
To support the European Commission in the development of the European QA scheme, a Quality 
Assurance Scheme Development Group (QASDG) was established in 20153 following a Call for 
Expressions of Interest4 organised by DG SANTE to support the European Commission, under 
the JRC’s technical and scientific coordination. The European co-operation for Accreditation (EA) 
supports the European QA scheme by framing it within Regulation (EC) No 765/2008 of the 
European Parliament and of the Council (European legislation for accreditation)5 in view of its 
piloting and implementation. 
The European QA scheme’s scope (henceforth The Scope) represents QASDG’s first output. It is 
meant to describe:
• the interventions and services that will be covered by the European QA scheme;
• the dimensions of quality that will be included;
• how the scheme will be implemented in the European context, and within the European
legislation for accreditation.
To ensure from the outset of its development that the approach proposed for the European QA 
scheme will be feasible for different health systems, countries and contexts of breast cancer 
service delivery, stakeholders and individual citizens were invited by a call for feedback to provide 
their opinions on The Scope. This report is about the results of this exercise.
A second call for feedback, on the final version of the scheme’s Manual, will be launched before 
making the scheme publicly applicable once the European QA scheme’s requirements are 
available.
1  http://europa.eu/!JT66Pp
2 http://ecibc.jrc.ec.europa.eu/quality-assurance
3 http://ecibc.jrc.ec.europa.eu/working-groups
4 http://ec.europa.eu/health/major_chronic_diseases/diseases/cancer/call_ecibc_en.htm
5  Regulation (EC) No 765/2008 of the European Parliament and of the Council of 9 July 2008 set-
ting out the requirements for accreditation and market surveillance relating to the marketing of 
products and repealing Regulation (EEC) No 339/93  
(http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2008:218:0030:0047:en:PDF)
82 Methodology of the call for feedback
2.1 The questionnaire  
The public call for feedback was open from 17 February to 9 March 2016 (3 weeks) by an on-line 
questionnaire via the EU Survey tool available at the ECIBC web hub6. 
This on-line consultation was open to all and no pre-registration was required. In order to ensure 
good coverage through stakeholders’ typologies and through countries, several information 
channels were used: the ECIBC web hub, DG SANTE’s newsletter, and European Public Health 
Association’s (EUPHA) newsletter. In addition, all the entities and individuals included in the ECIBC 
contacts’ database received a pre-notification about the call on 5 February (a non-exhaustive 
list of those contacts is reported in an annual ECIBC publication (1-2)). A reminder e-mail was 
sent on 2 March 2016 and, finally, an e-mail was sent to thank all participants at the closure 
of the survey. At the moment of publication of this report and of The Scope on the ECIBC web 
hub, a similar strategy will be put in place to disseminate the information about the availability 
of these two key ECIBC documents.
Participants were invited to download and print The Scope and to read the First proposal of general 
requirements of a European QA scheme provided by EA7 before answering the questionnaire. 
Respondents could indicate how their contribution would appear: under their name (and consent 
to the publication of all the information in the contribution); anonymously (and consent to 
the publication of all the information in the contribution, except the name/the name of the 
organisation); or ask for confidential treatment of the contribution, allowing internal use within 
the European Commission only.
The online questionnaire was composed of five parts, plus a final free-text box for general 
comments. The full questionnaire is available in Annex I to this report.
All detailed responses for which the respondent consented to publication, even in anonymised 
format, are made available on-line in the ECIBC web hub.
• The first part of the questionnaire gathered information about the respondents. They had to
identify themselves and indicate whether they were replying as an ‘individual’ or ‘on behalf
of an organisation’. The responses from the ECIBC national contacts were considered as ‘an
organisation’, because it was implied that they responded on behalf of the corresponding
country.
• The second part contained questions on the European QA scheme with respect to the
European legislation for accreditation. Respondents were asked:
• whether they agree with the standards selected for accreditation and certification within
the European QA scheme (i.e. ISO 17065:2012 and ISO 15189:2012);
• how relevant are the proposed categories for the scheme owner requirements;
• whether additional scheme owner requirements are needed.
6  http://ecibc.jrc.ec.europa.eu/-/scope-of-the-european-quality-assurance-scheme-for-breast-can-
cer-services
7  http://europa.eu/!KF79pK
9• The third part related to the activities and conditions covered by the European QA scheme.
Respondents were asked:
• whether they agree with the list of services, interventions and diseases proposed;
• whether the outlined breast cancer screening pathway is applicable in the context of
their healthcare system;
• whether they consider the subprocesses proposed as relevant and whether additional
subprocesses are needed.
• The fourth part explored the applicability of the proposed modular approach to the
respondent’s country healthcare system.
• The fifth part contained questions on the European QA scheme’s contents. Respondents
were asked whether the descriptions of the Manual and of the indicators are clear, whether
further typologies of reference documents or further quality domains are needed.
Finally an open-text part at the end of the questionnaire offered respondents the option to add 
any further comments and to address items not covered by the questionnaire.
A functional mailbox (JRC-ECIBC@ec.europa.eu) managed by the JRC, was available for requests 
for technical support.
2.2 Data collection and processing
Data were collected by the JRC, including personal data which were treated pursuant to Regulation 
45/2001/EC on the protection of individuals with regards to the processing of personal data by 
the Community institutions and bodies and on the free movement of such data.
Only comments submitted before the deadline and related to the contents of the documents 
were considered. Comments were excluded if they contained complaints against institutions, 
personal accusations, irrelevant or offensive statements or material, or content not related to 
policy aspects relevant for the ECIBC or outside the scope of ECIBC’s activity. Comments on 
The Scope received only as free-text e-mails to the functional mailbox were discarded, and 
hence are not covered by this report and are not considered for the final version of The Scope.
A draft feedback report including descriptive tables of responses was shared with the QASDG 
chair, vice-chair and coordinators of the QASDG subgroups Organisation, scope and modules, 
Certification Processes, and Quality concepts and Keywords (glossary). In particular, this step 
was meant to screen the suggestions received via the call about modifications, deletions or 
addition of subprocesses and quality domains, according to their relevance for a full QASDG 
group discussion. 
After the chairs and subgroups had reviewed the tables of responses, all the members of QASDG 
were involved in discussing and taking decisions on how to incorporate and respond to the 
feedback received: a set of slides summarising the main results of the call for feedback and 
highlighting topics for discussion was prepared and presented on 16 March 2016 to the whole 
of QASDG at a meeting in Varese. Decisions taken during that meeting were recorded in the 
minutes8. The corresponding changes were implemented in the final version of the The Scope, 
8 http://europa.eu/!uq37wQ
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which was eventually approved by QASDG on 16 May 2016. The new version including the 
changes highlighted in red is reported as Annex 2.
In this report, aggregated data are displayed for all the responses received. Comments received 
from individuals and entities requiring anonymisation are reported without the name of the 
contributor, whilst comments from individuals and entities asking for confidential treatment 
of the contribution are not reported at all. The full database of received responses, with the 
exception of confidential ones, is available through the ECIBC web hub.
Sensitivity analyses were performed separately, for responses received from individuals and from 
organisations. As no relevant difference was detected, data from individuals and organisations 
are reported together.
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3. Results 
3.1 Information about respondents
The JRC received a total of 63 valid responses, from 15 individuals (24 % of total) and 
48 organisations (76 %). Please note that affiliation is based on self-identification by respondents 
and has not been validated.
Figure 1. Distribution of survey responses to the public call for feedback (n=63) 
The vast majority of responses from individuals, 13 out of 15, identified themselves as professionals 
working in an area related to breast cancer. No one identified him/herself as a patient/consumer 
or family member. Two individuals asked for anonymisation of their contribution and another two 
individuals asked for confidential treatment of their contribution.
Figure 2. Survey responses from individuals (n=15)
All responses, except one from Norway, came from EU individuals, representing 11 out of 28 
Member States. All the respondents but one reported having become aware of the public call 
for feedback by the e-mail received from the JRC. Two of the 15 individuals happen also to be 
nominated ECIBC National Contacts.
As an individual
On behalf of an 
organisation
24%
76 %
Other
Professional working 
in areas related to 
breast cancer
13 %
87 %
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Figure 3. Geographical distribution of survey responses from individuals (n=15)
Forty-eight contributions were received from organisations, corresponding to 46 different 
entities. Kooperationsgemeinschaft Mammographie (Mammography Cooperative) and Deutsche 
Akkreditierungsstelle GmbH (DAkkS) contributed with two responses each. Their answers are 
counted twice in the pie-charts, whilst they are counted once when the number of organisations 
is reported in the text. Of the 48 responses on behalf of organisations, most of them came from 
professional societies or organisations (23 %), from national accreditation bodies (NABs) (19 %), 
and healthcare organisations (13 %). Replies were received from ECIBC National Contacts from 
five countries. Fourteen entities asked for anonymisation of their contributions and five entities 
asked for the confidential treatment of their contributions.
Figure 4. Survey responses from organisations, according to the type of 
organisation (n=46)
1. National
accreditation body 
19 %
2. Certification body
or conformity assessment body 
8 %
3. Organisation providing
quality assessement to 
healthcare institutions  
11 %
4. Healthcare organisation
13 %
5. Professional society
or organisation 
23 %
6. ECIBC
National contact 
8 %
7. 
Academic/ 
Research 
institution 
2 %
8. Industry
6%
9. Patient
advocacy 
organisation 
4 % 
10. Other
6 %
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Table 1. List of organisations contributing to the call for feedback and not 
asking for anonymisation or confidentiality.
NAME TYPE COUNTRY
Accreditation Canada
Organisation providing quality assessment 
to healthcare institutions  (e.g. hospital 
accreditation, breast cancer certification)
Canada
Association of Breast Surgery of Great 
Britain and Ireland (ABSGBI) Professional society or organisation UK
Associazione Senonetwork Italia Onlus Professional society or organisation Italy
Bulgarian Association for Medical Oncology Professional society or organisation Bulgaria
Catalan Cancer Plan. Catalonia. Spain ECIBC National contact Spain
Department of Cancers screening, Ministry 
of Health
Organisation providing quality assessment 
to healthcare institutions (e.g. hospital 
accreditation, breast cancer certification)
Luxembourg
Deutsche Akkreditierungsstelle GmbH (DAkkS) National accreditation body Germany
East Tallinn Central Hospital Healthcare organisation  (e.g. hospital, local health authority) Estonia
Erasmus University Medical Center 
Rotterdam
Healthcare organisation  
(e.g. hospital, local health authority) Netherlands
Estonian Society of obstetrics and 
Gynaecologists
Healthcare organisation  
(e.g. hospital, local health authority) Estonia
European Association for Palliative Care Professional society or organisation Finland
European CanCer Organisation (ECCO) 
response on this occasion is based on 
input from European Society for Medical 
Oncology (ESMO), European Society of 
Surgical Oncology (ESSO), European 
Society for Radiotherapy & Oncology 
(ESTRO), European Oncology Nursing 
Society (EONS) and European Association 
of Nuclear Medicine (EANM)
Professional society or organisation Belgium
European Reference Organisation for 
Quality Assured Breast Screening and 
Diagnostic Services (EUREF)
Certification body or conformity assessment 
body Netherlands
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Responses came from 20 EU countries, two European countries outside the EU (Montenegro, 
Serbia) and two non-European countries (Canada, Kuwait). The two countries with the highest 
number of contributors were Germany (eight, from five different organisations) and Italy (six, 
from six organisations). 
The respondents indicated they became aware of the public call for feedback mainly through 
the e-mail received from the JRC; other sources reported included refererences to DG SANTE’s 
newsletter and personal communication from a colleague.  
NAME TYPE COUNTRY
European Society for Medical 
Oncology (ESMO), European 
Organisation for Research and 
Treatment of Cancer (EORTC) 
and Champalimaud Foundation
Healthcare organisation  
(e.g. hospital, local health authority) Portugal
European Society for 
Radiotherapy & Oncology 
(ESTRO)
Professional society or organisation Germany
European Society of Breast 
Cancer Specialists (EUSOMA) Professional society or organisation Italy
European Society of Radiology Professional society or organisation Austria
German Cancer Society - 
Working Group of Pathology Professional society or organisation Germany
Ghent University hospital — on 
behalf of the breast care nurses 
and clinical nurse specialists
Academic / Research institution Belgium
ITALCERT Srl Certification body or  conformity assessment body Italy
Kooperationsgemeinschaft 
Mammographie (Mammography 
Cooperative)
Organisation providing quality assessment 
to healthcare institutions (e.g. hospital 
accreditation, breast cancer certification)
Germany
Ministry of Health of Republic  
Lithuania Other Lithuania
Office of Chief Medical Officer,  
Budapest, Hungary ECIBC National contact Hungary
OnkoZert GmbH Certification body  or conformity assessment body Germany
Pfizer Industry Belgium
Sociedad española de senologia 
y patología mamaria Professional society or organisation Spain
’Survive & Thrive’ initiative for 
cancer patients support Patient advocacy organisation Kuwait
15
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Figure 5. Geographical distribution of survey responses from organisations 
(n=48). In total, individuals and organisations from 23 out of 28 Member 
States (82 %) contributed to this public call for feedback
In the following paragraphs the results of the call for feedback will be reported question by 
question. Thereby the comments will be presented in an aggregated manner first, followed by 
a box, showing QASDG’s response to the comments. As already stated, the complete original 
version of the contributions, with the exception of confidential ones, is available through the 
ECIBC web hub.
3.2 Use of accreditation standards for the European QA scheme
3.2.1 Standard ISO 17065:2012
The first question on the European QA scheme investigated whether the respondent agreed with 
the use of the standard ISO/IEC 17065:2012 for accreditation of certification bodies that will run 
the scheme. 
Thirty-five organisations and 12 individuals (response rate: 76 %) responded. All responses 
but one were in favour of the use of this standard. We cannot report the comments supporting 
the negative reply, as it came from an individual asking for confidential treatment of his/her 
contribution.
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Figure 6. Agreement with the use of standard ISO/IEC 17065:2012. All the 
respondents (n=63)
3.2.2 Standard ISO 15189:2012
This question investigated whether the respondent agreed with the use of the standard ISO 
15189:2012 for accreditation of testing and examination activities. Thirty-seven organisations 
and 12 individuals (81 % in total) responded. Only six (11 %) disagreed with the use of this 
standard. 
Figure 7. Agreement with the use of standard ISO 15189:2012. All the 
respondents (n=63)
Two main concerns were raised by respondents on the use of ISO 15189:2012 accreditation and 
were associated with negative replies.
• Existence of other standards on testing services already in use and appropriate to the 
context. These other standards can be either inside the European legislation for accreditation 
(ISO/IEC 17020:2012 inspection for pathology laboratories in Germany — comment 
submitted by DAkkS, German Cancer Society - Working Group of Pathology, OnkoZert 
GmbH, and a contributor requiring anonymisation), or outside (i.e. Biomedical Laboratory 
and Diagnostic Imaging standards in the Accreditation Canada’s Qmentum International 
Accreditation Program — comment submitted by Accreditation Canada). 
I prefer to skip the 
question
No
Yes
11 %
19 %
70 %
I prefer to skip the 
question
No
Yes
24 %
3 %
73 %
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In order to address the comments received, in particular those associated with negative 
replies and with concerns on the existence of other standards on testing services already 
in use, QASDG implemented a modification to The Scope, where a new sentence was 
added:
‘For testing activities ISO 15189:2012 will be used. Possible time and equivalence 
derogations will be covered within the Scheme Owner’s requirements along the 
discussion and approval processes of the QASDG.’
Moreover, even if the European QA scheme is run under the European legislation for 
accreditation, the International Society for Quality in Healthcare (ISQua) is one of the 
reference models, as already mentioned in The Scope: 
‘The Manual may be inspired by recommendations such as the ones from the ISQua 
International Accreditation Programme (IAP).’
ISO 15189:2012 is already implemented for imaging services in at least two countries: 
the United Kingdom (via the Imaging Services Accreditation Scheme (ISAS) standard) and 
New Zealand. Please refer to the following websites for further information: 
https://www.isas-uk.org/
http://www.ianz.govt.nz/services/accreditation-2/accreditation/laboratories/medical/
Finally, regarding the suggestion received on restricting the use of ISO 15189:2012 to 
outsourced services, according to ISO 17065:2012, an already accredited ISO 15189:2012 
imaging process must not be certified, having ‘presumption of conformity’ to certification’s 
management requirement (according to Sept. 2009 IAF ILAC ISO Joint Communiqué). 
Accreditation to ISO 15189:2012 should be ‘complete’ and cannot be restricted 
only to a sub-process such as outsourcing services being, these services, included in 
ISO 15189:2012 requirements.
• Direct application of ISO 15189:2012 to imaging services as this standard was developed
for medical laboratories (comment submitted by Accreditation Canada).
Among those agreeing on the application of ISO 15189:2012 accreditation for testing services, 
similar concerns were also raised together with the suggestion, from the Kooperationsgemeinschaft 
Mammographie (Mammography Cooperative), to restrict the use of ISO 15189:2012 to 
outsourced services such as pathology, while imaging services within screening and diagnostics 
should simply be covered by the certification process.
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Yes   No   Skip
A  B  C  D  E  F
A:  Methodology for requirements’ rating, weighting, 
aggregation rules, and threshold for each section
B: Audit and surveillance requirements
C: Pre-assessment procedures
D: Assessment strategies
E: Post-assessment procedures
F:  Competences requirement of assessors/auditors  
and their maintenance over time
3.2.3 Certification scheme requirements (scheme owner requirements)
This question investigated whether the proposed scheme owner requirements were considered 
relevant. Respondents were asked to rate each scheme owner requirement with ‘yes’ or ‘no’ or 
‘skip this question’. 
Seventy-nine per cent of respondents rated each requirement as ‘yes’ or ‘no’. Some of the 
respondents who agreed with the proposed requirements also added comments, e.g. ‘prioritization 
of requirements through a «weighting» system’ (Accreditation Canada), ‘a steering committee 
to govern the audits’ (contribution from an organisation requiring anonymisation), ‘direct 
observation in screening performance at site (visit) including review of interval cancers, review 
of clinically worked-up cases, and attending multidisciplinary meeting’ (European Reference 
Organisation for Quality Assured Breast Screening and Diagnostic Services — EUREF).
Concerns reported by respondents disagreeing with some of the proposed requirements often 
related to the fact that these would depend on national characteristics. In particular, these 
concerns arose with the auditing strategies, the composition of auditor teams, availability of 
external experts, format and style of reports, award decisions or appeals to award decisions 
(comments submitted by Kooperationsgemeinschaft Mammographie).
Figure 8. Relevance of scheme owner requirements. All the respondents (n=63)
Two-thirds of respondents declared that no further scheme owner requirements would be needed. 
Two organisations suggested possible additional scheme owner requirements: ‘Checklist for cancer 
patients to fill to confirm their awareness of the complete process of their service’ (comment 
submitted by ‘Survive & Thrive’ initiative for cancer patients support); ‘Having a clear goalsetting 
before starting a quality assurance’ and ‘Follow up sessions: internal and with external auditors’ 
(comments submitted by Ghent University hospital on behalf of the breast care nurses and 
clinical nurse specialists). One individual suggested that ‘Additional requirements not currently 
foreseen may emerge as the scheme develops and should be added as necessary’. One entity 
proposed an additional scheme owner requirement, but asked for confidential treatment of its 
contribution.
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I prefer to skip the 
question
No
Yes
No changes were implemented to The Scope regarding the scheme owner requirements. 
However, all the suggestions and comments received on scheme owner requirements 
will be discussed by QASDG for the preparation of a specific document on scheme owner 
requirements, which is foreseen to be issued together with the European QA scheme 
Manual. ECIBC National Contacts will be involved in evaluating the feasibility of the 
European QA scheme before it is piloted, and those breast cancer services selected for 
piloting will also contribute to ensuring that the European QA scheme will be implementable 
in all countries.
Figure 9. Need for other scheme owner requirements. All the respondents 
(n=63) 
3.3 Services, interventions and diseases covered by the European QA 
scheme
This question focused on services, interventions and diseases that the European QA scheme 
covers. Forty-two organisations and 13 individuals (90 % of total respondents) answered this 
question. Close to 90 % of respondents were in favour of the proposal made in The Scope. 
Figure 10. Agreement with services, interventions and diseases covered. All 
the respondents (n=63)
32 %
8 %
60 %
Generally, I agree with it; 
see comments below
I agree with it, I do not 
have comments
I have concerns;  
see comments below
I prefer to skip this 
question
17 %
10 %
2 %
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More details on processes, addressing the comments received on treatment and screening, 
will not be apparent in The Scope, but will be covered in future QASDG documents. In 
particular, citizens’ education for screening is considered to be included in the subprocess 
‘Patient involvement-empowerment’ (e.g. ‘communication of the diagnosis and treatment 
plan, patient information, patient navigation, shared decision making’), whilst primary 
prevention is included in the new subprocess called ‘Primary prevention and health promotion’.
Male breast cancer and benign breast diseases do not fall under the scope of the European 
QA scheme. However, its blueprint may be adapted to breast cancer in male subjects in the 
context of a future project following the pilot run for female breast cancer, whilst other non-
malignant breast diseases are covered by the scheme when implied in a differential diagnosis 
of cancer.
Only one organisation (Pfizer) expressed concerns, commenting on the application of the 
European QA scheme to treatments. Concerns related, in particular, to the use of medicines, 
the interaction with the medicines regulatory framework (governed by the European Medicines 
Agency and national regulators) and the divergent availability of medicines in different countries 
due to e.g. a lack of reimbursement. 
Among the other comments received, the main concerns were about the inclusion of diseases 
and the inclusion/modification/clarification of services in the European QA scheme:
• male breast cancer (input received from Association of Breast Surgery of Great Britain and
Ireland - ABSGBI)
• benign breast diseases (input received from ABSGBI)
• education before screening (input received from two organisations requesting anonymisation)
• possible inclusion of general practictioner referral of symptomatic women
(Kooperationsgemeinschaft Mammographie and Catalan Cancer Plan)
• surveillance should be moved after rehabilitation (Catalan Cancer Plan)
• clarifications about primary prevention vis-á-vis the ECIBC’s proposed pathway (The Office
of the Chief Medical Officer (Budapest) and the Catalan Cancer Plan).
3.3.1 Breast cancer care pathway
This question investigated whether the breast cancer treatment pathway proposed was considered 
applicable in the respondent’s own country. Thirty-nine organisations and 15 individuals (87 % of 
the total) provided an answer, representing a total of 22 countries out of the 23 covered.
Almost three-quarters of respondents (74 %) found the proposed pathway applicable in their 
country. Eight respondents (2 individuals and 6 organisations) from 6 countries (Belgium, 
Finland, Germany, Malta, Luxembourg, the Netherlands) declared that the pathway would not be 
applicable. A comment from Germany, received by one of the two responding individuals, could 
not be considered as it did not address the topic of the question.
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Figure 11. National applicability of breast cancer care pathway. All the 
respondents (n=63)
All other comments addressed non-country-specific issues, and expressed suggestions or 
disagreements with one or more of the features of the breast cancer care pathway. For example, 
suggestions were received on:
• adding an arrow from the diagnosis box back to screening (input received from Erasmus
University Medical Center Rotterdam);
• having a dedicated pathway for metastatic breast cancer (input received from Pfizer);
• mentioning the context of healthcare — e.g. ‘What is happening in the hospital’; ‘Which
phase is situated in primary care’ (input received from Ghent University hospital on behalf
of the breast care nurses and clinical nurse specialists);
• adding ‘death as an outcome’ at any step after diagnosis (input received from the
Department of Cancers screening, Ministry of Health, Luxembourg).
The European Association for Palliative Care (EAPC) used the free-text box at the end of the 
questionnaire to express a request for a better definition of  ‘palliative care’.
3.3.2 Subprocesses
For this section two questions were addressed: the first investigated whether the proposed 
subprocesses were considered relevant; the second asked for suggestions on additional 
subprocesses that may be needed. 
Forty-three organisations and 12 individuals (response rate 87 %) replied to the first question 
and 74 % of respondents felt the proposed subprocesses were relevant.
Thirty-six organisations and 12 individuals (response rate 78 %) replied to the second question 
and 49 % believed that additional subprocesses were not needed, whilst 29 % proposed additional 
subprocesses. 
Suggestions for modifications, deletions or addition of subprocesses were first screened by the 
I prefer to skip the 
question
No
Yes
13 %
13 %
74 %
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JRC, the QASDG chair, the vice-chair and the coordinators of the subgroup for Organisation, 
scope and modules, the subgroup on Certification Processes, and the subgroup on Quality 
concepts and Keywords (glossary). The suggestions considered as relevant for a discussion by 
QASDG were presented at the 16 March 2016 meeting and then approved or rejected by QASDG. 
Details on the decision procedure are reported in the meeting’s minutes9 and the results are 
summarised in the box below.
Figure 12. Relevance of subprocesses. All the respondents (n=63)
Figure 13. Need for additional subprocesses. All the respondents (n=63) 
9 See footnote 8 
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The most significant changes to The Scope following the review process triggered by this 
part of the call for feedback included the following:
• Inclusion of a new subprocess named ‘Prevention and health promotion’ (prompted 
by inputs received in other sections of the questionnaire from two organisations 
requiring anonymisation).
• Inclusion of a new subprocess named ‘Governance’ (prompted by input from an 
individual).
• Renamed the imaging subprocess as ‘Imaging and imaging-guided interventions’ 
(prompted by input from the European Society of Radiology).
• Added a new subprocess ‘Quality assurance of equipment imaging and therapy 
devices’ (prompted by input from an entity requiring anonymisation).
• Added a new subprocess called ‘Fertility preservation’ (prompted by input from an 
entity requiring anonymisation).
• Added ‘Medications management’ to the subprocess ‘Patient safety’ (prompted by 
input from an individual).
Most of the other subprocesses suggested in the feedback were already considered by 
the existing ones, e.g.: 
• ‘Breast Information systems to track and store patient data’ (input received from 
two entities requiring anonymisation) within ‘Data management (databases and 
registries)’; 
• ‘Document control’ (input received from an entity requiring anonymisation) within 
‘Quality Management’; 
• ‘Patient and family engagement’ (Accreditation Canada) within ‘Patient involvement-
empowerment’; 
• ‘Information transfer’ (Accreditation Canada) within ‘Team collaboration including: 
multidisciplinary meeting / tumour board’; 
• ‘Handover’ within ‘Data management (databases and registries)’. 
Two entities requiring anonymisation suggested a list of specific imaging techniques to be 
separately included. In this case QASDG considered that the suggestions were globally 
covered by the ‘Imaging and imaging-guided interventions’ and the ‘Quality assurance of 
equipment imaging and therapy devices’ subprocesses. 
A further entity requiring anonymisation made suggestions on the allocation of 
subprocesses to the six main processes of care. In this case, all the corrections 
suggested were implemented except the one asking to delete the complementary and 
integrative approach subprocess from the screening process, because in this case use of 
complementary approaches should be intended as contributing to the control of anxiety 
during the assessment phase. 
Also a comment on the subprocess ‘symptom control’ in the screening process, submitted 
by ESMO, EORTC, Champalimaud Foundation and ECCO in the free-text box at the end of 
the questionnaire, was not addressed with a modification in The Scope, because symptom 
control in screening is to be intended as pain control during mammography, addressing 
anxiety, etc.
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3.4 The modular approach
The first question investigated whether the modular approach proposed was considered applicable 
in the respondent’s own country. Thirty-one organisations and 12 individuals (response rate 
70 %) responded, representing a total of 21 EU countries, plus Norway and Serbia.
All the respondents, except for one (an entity requiring anonymisation), considered the modular 
approach applicable in their countries. However, two other respondents from the same country 
instead stated that the modular approach proposed would be applicable. 
An entity requiring anonymisation replied that none of the outlined options would be feasible 
in Germany due to the preconditions of the healthcare system. However, the option closest to 
applicability would be option 3B, the entity stated. 
Figure 14. Applicability of the modular approach. All the respondents (n=63)
The second question asked respondents to indicate whether the proposed scenarios would 
be implementable in their country. Thirty-five entities (12 individuals and 23 organisations) 
responded. 
Figure 15. Applicability of scenarios. Valid responses (n=35)
Applicable
0
5
10
15
20
25
30
35
1A 1B 2A 2B 3A 3B
I prefer to skip the 
question
No
Yes
30 %
65 %
5 %
25
In order to guarantee the implementability of the European QA scheme in each European 
country, it is in principle sufficient that a single modular scenario is applicable in a given 
country. As this is apparently the case, according to the replies received, no changes 
were made to this part of The Scope.
The two scenarios where the breast cancer screening programme and the breast centre are 
under the same legal entity (1A and 1B) were seen as less implementable with respect to the 
other ones, although around half of the respondents declared the two scenarios were anyway 
implementable. 
Scenarios characterised by the networking model received the most consensus concerning 
applicability, both with end-of-life care being integrated in the breast centre and with not being 
integrated.
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Country Organisation 1A 1B 2A
Austria European Society of Radiology Applicable  - Applicable
Belgium
Ghent University hospital - on 
behalf of the breast care nurses 
and clinical nurse specialists
Applicable Applicable Applicable
Belgium Anonymous entity Not applicable Applicable Applicable
Bulgaria Bulgarian Association for Medical Oncology Not applicable Not applicable Applicable
Estonia East Tallinn Central Hospital Applicable Applicable Applicable
Estonia
Estonian Society of 
Obstetricians and 
Gynaecologists
Applicable Applicable Applicable
Finland European Association for Palliative Care Not applicable Not applicable Applicable
Finland Anonymous entity  -  - Applicable
France Anonymous entity Not applicable Applicable Applicable
Germany ESTRO Not applicable Applicable Not applicable
Germany
Kooperationsgemeinschaft 
Mammographie (Mammography 
Cooperative)
Not applicable Not applicable Not applicable
Germany OnkoZert GmbH  - Not applicable  -
Italy Anonymous entity Applicable Applicable Applicable
Italy Associazione Senonetwork Italia Onlus Not applicable Not applicable Applicable
Italy ITALCERT Srl Not applicable Not applicable Applicable
Italy EUSOMA Not applicable Not applicable Applicable
Lithuania Ministry of Health Applicable Applicable Applicable
Luxembourg Department of Cancers screening, Ministry of Health Not applicable Not applicable Not applicable
Netherlands EUREF Not applicable Not applicable Not applicable
Portugal On behalf of ESMO, EORTC and Champalimaud Foundation Applicable Applicable Applicable
Spain Sociedad española de senologia y patología mamaria Applicable Applicable Applicable
Spain Catalan Cancer Plan, Catalonia, Spain Applicable Applicable Applicable
Sweden Anonymous entity Applicable Applicable Applicable
Table 2. Individual respondents’ replies on the applicability of the scenarios
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Country Organisation 2B 3A 3B
Austria European Society of Radiology  - Applicable  -
Belgium
Ghent University hospital - on 
behalf of the breast care nurses 
and clinical nurse specialists
Applicable Applicable Applicable
Belgium Anonymous entity Applicable Applicable Applicable
Bulgaria Bulgarian Association for Medical Oncology Applicable Applicable Not applicable
Estonia East Tallinn Central Hospital Applicable Applicable Applicable
Estonia
Estonian Society of 
Obstetricians and 
Gynaecologists
Applicable Applicable Applicable
Finland European Association for Palliative Care Applicable Applicable Applicable
Finland Anonymous entity Applicable Applicable Applicable
France Anonymous entity Applicable Applicable Applicable
Germany ESTRO Applicable Not applicable Applicable
Germany
Kooperationsgemeinschaft 
Mammographie (Mammography 
Cooperative)
Applicable Not applicable Applicable
Germany OnkoZert GmbH Not applicable  - Not applicable
Italy Anonymous entity Applicable Applicable Applicable
Italy Associazione Senonetwork Italia Onlus Applicable Applicable Applicable
Italy ITALCERT Srl Applicable Applicable Applicable
Italy EUSOMA Applicable Applicable Applicable
Lithuania Ministry of Health Applicable Applicable Applicable
Luxembourg Department of Cancers screening, Ministry of Health Not applicable Not applicable Applicable
Netherlands EUREF Applicable Not applicable Applicable
Portugal On behalf of ESMO, EORTC and Champalimaud Foundation Applicable Applicable Applicable
Spain Sociedad española de senologia y patología mamaria Applicable Applicable Applicable
Spain Catalan Cancer Plan, Catalonia, Spain Applicable Applicable Applicable
Sweden Anonymous entity Applicable Applicable Applicable
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3.5 The European QA scheme’s contents
3.5.1 The Manual of requirements and the indicators 
The first question asked whether the description of the Manual of requirements was clear enough. 
Thirty-six organisations and 14 individuals (response rate 81 %) responded.
About two-thirds of respondents (68 %) considered the description of the Manual to be clear. 
Most of the comments indicating that the Manual was not sufficiently clear concerned details 
that should be provided, in particular if and how existing requirements and quality indicators 
(EUSOMA) will be used as a starting point (input received from EUSOMA, from ECCO — the 
response on this occasion was based on input from ESMO, ESSO, ESTRO, EONS and EANM — and 
from an answer on behalf of ESMO, EORTC and the Champalimaud Foundation).
Figure 16. Clarity of Manual description. All the respondents (n=63)
The second question investigated whether respondents found that the description of the indicators 
was clear enough. Thirty-seven organisations and 15 individuals (response rate 84 %) responded.
Three-quarters (75 %) considered that the description of the indicators was clear. The comments 
received from those disagreeing on the clarity of the indicators were similar to those received 
for the Manual. They asked in particular if and how existing quality indicators (EUSOMA) will 
be used as a starting point (input received from ECCO — the response on this occasion was 
based on input from ESMO, ESSO, ESTRO, EONS and EANM — and from an answer on behalf of 
ESMO, EORTC and the Champalimaud Foundation). An individual contributor suggested including 
not only quantitative indicators but also qualitative indicators such as patient satisfaction, self-
management patient and partner, knowledge and expertise professionals, etc., and having 
a minimal set of indicators such as clinical outcomes, patient outcomes, process outcomes, 
professional outcomes, organisation outcomes, and network outcomes.
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Figure 17. Clarity of indicator description. All the respondents (n=63)
Finally, the questionnaire asked whether the description of the methods for the development of 
requirements and indicators was considered clear. Thirty-seven organisations and 15 individuals 
(84 % of the total) responded.
More than two-thirds (70 %) considered the description of the method for the development of 
requirements and indicators as clear.
Figure 18. Clarity of the description of the methods for the development of 
requirements and indicators. All the respondents (n=63)
Comments stating that the methods were not clearly described were similar to those received for 
the Manual and indicators, in particular asking for more details that should have been provided, 
and if and how existing quality indicators (EUSOMA) will be used as a starting point (input 
received on behalf of ESMO, EORTC and Champalimaud Foundation and from ECCO). Details that 
were suggested for inclusion in the methodology were:
• A SMART  (Specific – Measurable – Assignable – Realistic –  Time-related) description of
indicators and more examples (input received from Ghent University hospital on behalf of
the breast care nurses and clinical nurse specialists, Belgium).
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• More references to the Delphi-like rounds and how they translate into a valid and reliable 
result (input received from an individual).
• How understandability, measurability, behaviourability and achievability of indicators (all 
listed in the RUMBA criteria) are addressed by the Delphi-like rounds (input received from 
the Catalan Cancer Plan, Catalonia, Spain).
• Who will be included in the Delphi-like rounds and how long this process is expected to take 
(input received from an individual).
3.5.2 Reference documents
Via this question respondents were asked to suggest further reference documents that might be 
needed. Thirty-one organisations and 11 individuals (response rate 67 %) responded.
Almost half of the respondents (49 %) found that additional reference documents were not 
needed, whilst 18 % proposed additional reference documents.
In two cases, the respondent (an individual and an entity that required anonymisation) suggested 
a general category of reference documents that may be needed: ‘Psycho-social screening and 
assessment in oncology and palliative care settings’ and ‘Guidelines for breast cancer for whole 
breast cancer service (treatment, rehabilitation...)’.
In all the other cases, the respondents indicated specific documents to be considered as reference 
documents:
• ‘ESMO Guidelines Early Breast Cancer’ (input received from ESMO, EORTC and Champalimaud 
Foundation, and from ECCO);
A specific document on the project’s methodology was made available on the ECIBC 
website: http://ecibc.jrc.ec.europa.eu/-/methods-of-the-voluntary-european-quality-
assurance-scheme-for-breast-cancer-services 
In this document the aspects reported as unclear by the respondents are now explained. 
For example, from this document it may be inferred that the EUSOMA requirements and 
quality indicators will be considered, together with requirements and indicators from 
other existing quality schemes, for inclusion in the source requirements that will be used 
for the Delphi-like rounds. 
In the list of documents serving as a basis for the Manual, only non disease-specific 
guidance for the development of healthcare quality recommendations is cited (i.e. from 
the ISQuA and from the National Institute for Health and Care Excellence), as such 
general guidance provides the theoretical frame for structuring breast cancer specific-
requirements, for instance along quality dimensions. For this reason, none of the existing 
breast cancer-specific sets of requirements and indicators, including EUSOMA, are cited 
in this part of The Scope.
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• ‘St Gallen Consensus Guidelines Primary Breast Cancer’ (input received from ESMO, EORTC 
Champalimaud Foundation, and from ECCO);
• ‘ESO-ESMO Guidelines for Advanced Breast Cancer’ (input received from ESMO, EORTC 
and Champalimaud Foundation, and from ECCO);
• ‘National Comprehensive Cancer Network Guidelines for Breast Cancer’ (input received 
from ESMO, EORTC and Champalimaud Foundation, and from ECCO);
• ‘Swedish National Guidelines for treatment of breast cancer’ and ‘National Clinical Practice 
Guidelines’ for breast cancer (input received from an entity requiring anonymisation).
In the final free-text box for comments, an entity requiring anonymisation suggested the 
Health Information and Quality Authority’s ‘National Standards for Safer Better Healthcare’ for 
information on quality themes and capability and capacity themes.
The comment on the need of psycho-social screening and assessment reference 
documents will be taken into account for the broader reference documents category 
Core set of information to be recorded in the different processes of care, such as: […] 
d) medical records.
All the guidelines mentioned in the responders’ comments will be taken into account 
either via the call for reference documents or via the evaluation for inclusion in the 
ECIBC Guidelines Platform (3).
I prefer to skip the 
question
No
Yes
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Figure 19. Need for other typologies of reference documents. All the respondents 
(n=63) 
3.5.3 Quality domains
This question asked the respondent to suggest further quality domains that might be appropriate 
for the European QA scheme. Thirty-nine organisations and 12 individuals (response rate 82 %) 
responded.
The majority of respondents (65 %) did not consider the need for additional quality domains, 
whilst 17 % proposed additional quality domains.
Figure 20. Need for more quality domains. All the respondents (n=63) 
As already seen for subprocesses, suggestions for modifications, deletions or addition of quality 
domains were first screened by the JRC, the QASDG chair, the vice-chair and the coordinators 
of the subgroup for Organisation, scope and modules, the subgroup on Certification Processes, 
and the subgroup on Quality concepts and Keywords (glossary). The suggestions considered as 
relevant for a discussion by QASDG were presented at the 16 March meeting and then approved 
or rejected by QASDG. Details on the decision procedure are reported in the meeting’s minutes10.
The additional quality domains proposed were:
• professional competencies (input received from an entity requiring anonymisation);
• patients awareness and prevention (input received from the ‘Survive & Thrive’ initiative);
• cost-effectiveness (input received from ESMO, EORTC and the Champalimaud Foundation, 
and by ECCO);
• medical devices (input received from an entity requiring anonymisation);
10 See footnote 7
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• quality-of-life (input received from the European Association for Palliative Care);
• use of information (input received from an entity requiring anonymisation);
• multidisciplinary protocols (input received from Ghent University hospital on behalf of 
breast care nurses and clinical nurse specialists, Belgium)
• education and expertise of professionals (input received from Ghent University hospital on 
behalf of breast care nurses and clinical nurse specialists, Belgium);
• vision of the breast cancer centre — management (input received from Ghent University 
hospital on behalf of breast care nurses and clinical nurse specialists, Belgium)
One individual and Pfizer included a comment on the ‘clinical effectiveness’ domain in the free-
text box at the end of the questionnaire. These comments required to clarify and/or broad the 
scope of this domain.
QASDG decided not to change the quality domains already proposed in The Scope. Cost 
effectiveness was considered an important issue and a new sentence was added to The 
Scope: ‘Cost-effectiveness is also an important dimension of service provision that should 
be taken into account in the European QA scheme’.
A new reference to the Organisation for Economic Co-operation and Development (OECD) 
definition was added to the quality domain for ‘clinical effectiveness’.
Other suggestions were considered to be already addressed by other quality domains or 
in the list of subprocesses:
• The ‘Facilities, resources and workforce’ domain may also include ‘Professional 
competencies’ and ‘Education and expertise of professionals’.
• The ‘Personal empowerment and experience’ domain may also include ‘Patients 
awareness and prevention’ and ‘Quality-of-life’.
• ‘Team collaboration including: multidisciplinary meeting/tumour board’ and the 
‘Handover’ subprocess may also include ‘Multidisciplinary protocols’.
• ‘Data management databases and registries’ may also include ‘Use of information’.
• The new ‘Governance’ subprocess may also include ‘Vision of the breast cancer 
center – management’.
• The ‘Medical devices’ domain is considered to be transversely addressed in the 
different subprocesses.
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3.6 General comments
Thirty-six respondents (twenty-nine organisations and six individuals) submitted a comment in 
the free-text box at the end of the questionnaire. Ten praised the ECIBC or The Scope, or thanked 
the JRC for providing the opportunity to give feedback. Most comments were constructive, even 
when expressing concerns, and no severe criticism of The Scope was expressed. In most cases 
the comments were linked to one of the sections of the previous questionnaire and in this Report 
they are reported in the specific paragraph.
A comment on the whole document (from the Office of Chief Medical Officer, Budapest, Hungary) 
addressed the language element, which was perceived as too technical. Future versions of The 
Scope and of other ECIBC’s outputs will also be developed in user-friendly language, in order to 
be more easily understood by all stakeholders.
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4. Conclusion
Globally, the results of this public call for feedback indicate that respondents appreciated 
the openness of the procedure and, in fact, this same degree of transparency will be applied 
throughout the ECIBC.
Overall, respondents represented the main categories of stakeholders (see Figure 4) and 
expressed acceptance and positive consideration of the main features of the European QA scheme 
as presented in The Scope. On average, the percentage of respondents agreeing with the items 
proposed in The Scope was about 70 %, and the negative responses were usually below 10 %. 
These general figures suggest that no major changes to The Scope need to be made. 
The JRC and QASDG carefully evaluated the feedback, in particular for the two points that were 
consistently raised by the respondents and/or countries:
• the applicability of ISO 15189:2012 as an accreditation standard for pathology laboratories 
in Germany, where this activity is considered as inspection and ISO/IEC 17020 is used;
• a lack of detailed information on the methodology proposed for the selection of requirements 
and indicators, in particular regarding the use of existing requirement sets, like the one 
used by EUSOMA.
For the first point, The Scope was amended in order to allow for the use of other standards 
proving to be equivalent to ISO 15189:2012. In respect to the description of the methodology, 
a new document is available on the ECIBC web hub11 describing in detail the processes of 
selecting requirements and indicators by using the Delphi methodology.
The relatively small number of replies received in total and, in particular, the lack of information 
from five EU Member States (Cyprus, Denmark, Romania, Slovakia and Slovenia) can be seen as 
a limitation to the significance of the results. However, the number and relevance of organisations 
(in some cases covering the whole Europe) contributing to this call for feedback can be considered 
as compensating factors for the limited number of replies and the five countries not covered.
On the other hand, the JRC will put in place a strategy to favour a wider coverage of the 
34 countries involved in the project, in particular for future steps relating to implementation (e.g. 
the scheme piloting).
The new version of The Scope, published together with this report, integrates a significant 
number of the inputs received and when feedback is not integrated, the reasons are clearly 
expressed in this Report. 
The call for feedback has led to an enriched document, thanks to the diversity and meaningfulness 
of contributions. This call for feedback can thus be considered a success and hopefully contributes 
to enhancing the future implementation of the European QA scheme and its potential impact on 
the quality of breast cancer care in Europe.
A new call for feedback will be launched on publication of the first version of the European QA 
scheme Manual, likely in 2018.
11 http://ecibc.jrc.ec.europa.eu/qa-methodology
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Annex 1
Call for feedback on the scope of the 
European Quality Assurance scheme 
for Breast Cancer Services
1Call for feedback on the scope of the European
Quality Assurance scheme for Breast Cancer
Services
Fields marked with * are mandatory.
From 17 February 2016 to 09 March 2016, the European Commission Initiative on Breast 
Cancer (ECIBC) is asking stakeholders for comments on the scope of the European Quality 
Assurance scheme for Breast Cancer Services.
Published:
17 February 2016
Privacy statement
* I confirm that I read and agree with the Privacy statement.
Privacy%20Statement%20%20JRC.pdf
Respondent's information
*Your full name
250 character(s) maximum 
*Your e-mail address for correspondence only (the e-mail address will not be disclosed under any
circumstances, please refer to the privacy statement)
* I am replying:
As an individual
On behalf of an organisation (including any association, authority, company or body)
2*Please select the category that you identify with best.
Consumer or patient
Family member or carer of a patient
Professional working in areas related to breast cancer screening or diagnosis, such as
radiologists, pathologists, epidemiologists, clinicians, policymakers, researchers, guideline
developers
Other
*Name of the organisation
250 character(s) maximum 
*Please select the category that you identify with best.
1. Patient advocacy organisation
2. Healthcare organisation
3. Professional society or organisation, including guidelines development organisations
4. ECIBC National contact
5. Academic / Research institution
6. Trade union
7. Industry
8. Other
*Your country
EU country
Non EU country
*EU country
Austria
Belgium
Bulgaria
Croatia
Republic of Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Ireland
Italy
3Italy
Latvia
Lithuania
Luxembourg
Malta
Netherlands
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
UK
Non EU country (please specify)
40 character(s) maximum 
*Do you agree to the publication of your contribution?
Yes (I consent to the publication of my contribution together with my name, and I declare that
none is subject to copyright restrictions that would prevent publication)
Yes (I consent to the publication of my contribution in an anonymous manner, and I declare that
none is subject to copyright restrictions that would prevent publication)
No (the contribution cannot be published, but the contribution may be used internally within the
Commission)
How you found out about this Call  for feedback?
E-mail from ECIBC
DG SANTE newsletter
Other (please mention)
Other source (please specify)
250 character(s) maximum 
41b. How accreditation is applied for the European QA scheme
*Do you agree with the standard selected for the accreditation scheme (ISO17065:2012)?
Yes
No
I do not wish to answer this question
Please include your comments.
500 character(s) maximum 
*Do you agree with the standard selected for testing and examination activities
(ISO15189:2012)?
Yes
No
I do not wish to answer this question
Please include your comments.
500 character(s) maximum 
General scope of the European Quality Assurance scheme for Breast
Cancer Services
5Yes No
*Methodology for requirements’ rating (e.g. numeric, Likert, non-conformity, etc.),
weighting (if any), aggregation rules, and threshold scores for each section
*Audit and surveillance requirements (e.g. frequency of audit and composition of
auditor team)
*Pre-assessment procedures (e.g. self-assessment, collection of information and
documents before the assessment, post-audit feedback from auditees, etc.)
*Assessment strategies (e.g. record reviews, interviews to professional staff and
patients, direct observation, etc.)
*Post-assessment procedures (e.g. on-site feedback to senior management,
evaluation and feedback from the auditees with regards to the assessors,
reporting format and style, procedure for validating draft final report and award
decision, appeals to awards decisions)
*Competences requirement of assessors/auditors and their maintenance over
time.
*Please include your comments.
500 character(s) maximum 
*Should other requirements be added?
Yes
No
I do not wish to answer this question
1c Certification scheme requirements (scheme owner requirements)
Are the certification scheme requirements mentioned appropriate?
Proposed requirements Please 
add one requirement/ row
Text
Requirement 1
Requirement 2
Requirement 3
Requirement 4
Requirement 5
Requirement 6
Requirement 7
Requirement 8
Requirement 9
Requirement 10
Requirement 11
Requirement 12
Requirement 13
Requirement 14
Requirement 15
6
72b The breast cancer treatment pathway
* Is the proposed breast cancer treatment pathway generally applicable in the context of your
healthcare system?
Yes
No
I do not wish to answer this question
Please include your comments.
500 character(s) maximum 
2c. Subprocesses
*Are the subprocesses mentioned appropriate?
Yes
No
I do not wish to answer this question
Please include your comments.
500 character(s) maximum 
8*Are more subprocesses needed?
Yes
No
I do not wish to answer this question
Proposed subprocesses 
Please add one subprocess/ row
Text
Subprocess 1
Subprocess 2
Subprocess 3
Subprocess 4
Subprocess 5
Subprocess 6
Subprocess 7
Subprocess 8
Subprocess 9
Subprocess 10
Subprocess 11
Subprocess 12
Subprocess 13
Subprocess 14
Subprocess 15
9
10
3a Modules and approaches for certification
* Is the modular approach applicable in the healthcare system in your country?
Yes
No
I do not wish to answer this question
Please include your comments.
500 character(s) maximum 
* Is at least one scenario applicable in your country?
Yes
No
I do not wish to answer this question
*Which one of the scenarios fits best in your healthcare setting?
One module approach
Two modules approach
Three modules approach
11
Thank you for your feedback!
General comments regarding the document
Please insert here comments related to the content of the document which were not addressed in the
above questions.
500 character(s) maximum 
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Annex 2
European Quality Assurance scheme 
for Breast Cancer Services  
Scope
Annex 2 is an extract of the scope of the European Quality Assurance scheme for 
Breast Cancer Services. It highlights in red the parts that have been modified 
accordingly to the suggestions received from the online call for feedback. The 
official scope document is published separately.
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This document concerns the scope of the European Quality Assurance scheme for Breast 
Cancer Services – in short, the European QA scheme.
The Directorate-General for Health and Food Safety (DG SANTE) asked the European 
Commission’s Joint Research Centre (JRC) to coordinate the European Commission 
Initiative on Breast Cancer (ECIBC). One objective of the ECIBC is to develop the European 
guidelines for breast cancer screening and diagnosis, while another is to develop the 
European QA scheme. This scheme will define a common set of quality and safety 
requirements for breast cancer services in Europe. It will cover all the relevant areas 
of healthcare provision for breast cancer and all breast cancer care procedures. It will 
define its requirements by considering evidence-based recommendations arising from 
high-quality guidelines, where possible, best professional practices and the relevant 
legislation. On completion, it will be piloted among participant services in Europe. 
A Quality Assurance Scheme Development Group (QASDG) was established in 2015 
following a call for expression of Interest1 organised by DG SANTE to support the EC in 
developing the European QA scheme, under the JRC’s technical and scientific coordination. 
European Cooperation for Accreditation (EA) will provide support for framing the 
European QA scheme within the European legislation for accreditation (Regulation (EC) 
No 765/2008)2 in view of its piloting and implementation.
This document represents the QASDG’s first output and is meant to describe: a) the 
interventions and services that will be covered by the European QA scheme; b) the 
quality dimensions that will be included; and c) how the scheme will be 
implemented in the European context, according to the European legislation for 
accreditation. All stakeholders and individual citizens were invited to provide their 
feedback on the draft document. The current document presents the results 
following the integration of the comments received. A second call for feedback will 
be launched once the European QA scheme’s requirements are available, and thus in 
the final version of the scheme’s manual. More information about the ECIBC is 
available on the initiative’s website3.
1 http://ec.europa.eu/health/major_chronic_diseases/diseases/cancer/call_ecibc_en.htm
2 Regulation (EC) No 765/2008 for Accreditation and Market Surveillance  
(http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2008:218:0030:0047:en:PDF)
3 http://ecibc.jrc.ec.europa.eu
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Box 4: Breast cancer service definition in the ECIBC
The operational definition of breast cancer service within the ECIBC is: ‘all 
healthcare services covering, in continuum, the full extent of breast cancer 
management, from screening to follow-up, and in some cases until the end-
of-life care’.
1.2 How accreditation is applied to the European QA scheme
In order to achieve consistency in the accreditation of conformity assessment bodies, 
NABs use harmonised standards. Since the European QA scheme will cover many 
healthcare procedures, including testing and examination activities, two main harmonised 
standards have been chosen: ISO 15189:2012 (Medical laboratories –- Requirements for 
quality and competence) for the testing activities and ISO/IEC 17065:2012 (Conformity 
assessment – Requirements for bodies certifying products, processes and services). Both 
standards will be directly used by the NABs: the first for accrediting testing activities 
(e.g. laboratories) associated to BCSs aiming to adhere to the European QA scheme, 
and the second for accrediting certification bodies ( CBs) which certify that the BCS 
fulfils all the specific requirements within the scheme. ISO 15189:2012 will be used 
for testing activities. Possible time and equivalence derogations will be covered within 
the scheme’s owner requirements during the discussion and the QASDG’s approval 
processes.  Figure 1 summarises how the European QA scheme will work.
Box 5: Definition of a ‘certification body’
“A certification body is by definition a legal entity or a defined part of a legal 
entity” (source: http://ul.com/customer-resources/ul-certification-bodies/)
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1.3  Certification scheme requirements (scheme owner 
requirements)
‘Accreditation and certification requirements’ include all the specifications on ‘how’ the 
‘service/process requirements’ will be audited and checked. 
For the BCS activities falling under ISO/IEC 17065:2012, those specifications will include:
• Methodology for rating requirements (e.g. numeric, Likert scale, non-
conformity, etc.), weighting (if any), aggregation rules, and threshold scores
for each section;
• Audit and surveillance requirements (e.g. frequency of audit and composition
of auditing team);
• Pre-assessment procedures (e.g. self-assessment, collection of information
and documents before the assessment, post-audit feedback from auditees,
etc.);
• Assessment strategies (e.g. record reviews, interviews with professional staff 
and patients, direct observation, etc.);
• Post-assessment procedures (e.g. on-site feedback to senior management,
evaluation and feedback from the auditees with regard to the assessors,
reporting format and style, procedure for validating draft final report and
award decision, appeals against awards decisions);
• Competency requirements of assessors/auditors and their maintenance over
time;
• If monitoring criteria for assessors is to be offered to NABs, the scheme owner
will have to monitor the technical performance of the standards, the scoring
system and feedback from the field (the clients and their customers – see
Figure 2).
For testing activities that will be accredited under ISO 15189:2012 or an equivalent 
standard, the ‘how’ is already defined both in the standard and in the NABs’ policies.
The EC as scheme owner would encourage the inclusion of a trained patient representative 
in the audits of the European QA scheme. Furthermore, the feasibility of a JRC-based 
central database of certification/accreditation outcomes will be tested during the pilot 
run. In fact, as scheme owner the EC is planning to maintain a central register of certified 
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2.  Services, interventions, diseases and
care processes covered
2.1. Services, interventions and diseases 
The European QA scheme applies to BCSs, as defined in Box 4: ‘all healthcare services 
covering, in continuum, the full extent of breast cancer management, from screening to 
follow-up, and in some cases until the end-of-life care’.
This includes:
• Primary prevention when the intervention is specifically targeted at breast
cancer (e.g. physical activity recommendations), although primary prevention
interventions in general may be included as ‘service/process requirements’
in one or more of the breast cancer procedures (e.g. smoking cessation or
alcohol reduction counselling in early diagnosis or treatment settings).
• Prevention (hormonal prevention or prophylactic mastectomy), surveillance,
diagnosis (including genetic testing), treatment, rehabilitation and palliative
care of breast cancer in women at increased risk of breast cancer also fall
within the scope of the scheme.
• Lesions pathologically defined as associated with ‘uncertain malignant
potential’ (so-called B3 lesions) also come under the scope of the scheme.
• Other non-malignant breast diseases are covered by the scheme when implied
in a differential diagnosis of cancer.
Male breast cancer and other male breast diseases, such as gynecomastia, do not fall 
under the scope of this scheme; its blueprint may be adapted to breast cancer in male 
subjects in the context of a future project following the pilot run for female breast cancer.
2.2. Breast cancer care pathway 
To ensure that accreditation and certification requirements follow a patient/person- 
centred approach, requirements will be defined by taking into account the care pathway 
(see Box 7) for breast cancer (and its related processes and sub-processes). 
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Box 7: Definition of ‘care pathway’
The care pathway describes the healthcare chain and interfaces 
across healthcare sectors by bundling and visualising the outcomes of the 
relevant healthcare processes involved and considering quality targets. In 
detail, the care pathway aims at:
• Presenting the intervention/processes for which quality should be
assured in a structured way;
• Presenting the relevant healthcare sectors involved;
• Assigning the responsibilities of healthcare providers to healthcare
processes;
• Identifying starting points for quality assurance;
• Identifying quality potential within the treatment pathway.
The care pathway visualises via a flow chart the pathway followed by 
a person. This flow chart includes specific services, end points, quality 
targets and quality potentials relevant to the specific subject of the quality 
assurance scheme and by considering the course of the disease as well as 
the various services involved. (source: AQUA-Institute: Allgemeine Methoden 
2015).
While dealing with breast cancer, persons go through different processes of 
care. Thereby, a general care pathway can be identified that applies to ‘typical cases’ of 
breast cancer. These care pathways are meant to be interpreted as a guide for the 
definition of requirements, and are not an exhaustive definition of all the possible 
variations of a general pathway, due to different local organisational settings, or 
specific individual cases of breast care that, for one reason or another, need to follow 
a different pathway. Existing descriptions of care pathways, e.g. the Washington 
State BCCHP Breast Care Algorithm9, may support the description of the processes. 
The simplified general care pathway proposed for the European QA scheme is 
represented in Figure 3.
9 http://www.kingcounty.gov/healthservices/health/chronic/bchp/~/media/health/publichealth/
documents/bchp/AlgorithmBreastCare.ashx
|  16
Figure 3: Breast cancer care pathway
Thus, the main stages of breast cancer care can be identified as follows:
• Screening
• Diagnosis
• Treatment10
• Rehabilitation
• Follow-up and survivorship care
• Palliative care11
Particular emphasis should thereby be given to requirements at the interface of the care 
processes, thereby addressing the quality dimension of continuity of care. One important 
example may be the availability of psychosocial support resources across all different 
processes, as considered appropriate for each case. The presence of a case manager 
(e.g. breast care nurse) throughout the entire continuum of procedures would facilitate 
the continuity of care. 
The connection with primary care (general practitioner) at the moment of referral for 
suspected cancer and for the management of the follow-up, where appropriate, should 
also be taken into account.
10 See WHO: http://www.who.int/topics/rehabilitation/en/ last accessed 11/2015 for definition
11 See WHO, 2002: http://www.who.int/cancer/palliative/definition/en/ last accessed 02/2016 for 
definition
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4.5 Quality domains
In the European QA scheme, classification of requirements will be proposed according to 
the following domains: 
• Clinical effectiveness18
• Facilities, resources and workforce
• Personal empowerment and experience
• Safety
The domains are derived from the three key quality domains identified in the Reflection 
Paper ‘Patient safety and quality of healthcare: actions at EU level’19 with the further 
inclusion of a domain for structures and workforce.
Several external cancer and breast cancer quality assessment schemes (4) consider 
research and training provided to other BCSs by reference centres as either separate 
domains, independent from the scheme’s other requirements, or as requirements 
associated with specific care processes/sub-processes. In other cases, they are considered 
as additional activities that should be performed by reference centres or high-complexity 
BCSs. Both research and training will be considered in the European QA scheme. 
Furthermore, the inclusion of additional transversal items may also be discussed by 
the QASDG. Such items refer to concepts that can be adopted from other existing 
classifications for different aspects of quality in health care, such as efficiency, access, 
equity, appropriateness, timeliness, acceptability, satisfaction, health improvement and 
continuity of care (9). Cost-effectiveness is also an important dimension of service 
provision that should be taken into account in the European QA scheme.
18 The word ‘effectiveness’ has been added on the basis of the NICE Healthcare quality standards 
process guide; as in the European QA scheme Manual, safety and effectiveness aspects will be 
tackled in two separate domains. ‘Effectiveness’ is defined as the degree of achieving desirable 
outcomes, given the correct provision of evidence-based healthcare services to all who could 
benefit (but not to those who would not benefit). This may include related dimensions of 
appropriateness, competence and capability (source: Organisation for Economic Co-operation 
and Development).
19 http://ec.europa.eu/health/patient_safety/docs/ps_qc_cons2013_background_en.pdf
The PDCA (plan-do-check-act) Cycle shows that the essential elements for a 
quality improvement system are defined requirements, compliance assessment 
methods, and incentives and mechanisms to enable improvement. The European QA 
scheme will adopt this view and will therefore focus on quality improvement20. 
Finally, a synopsis of the European QA scheme, including the manual, indicators and 
reference documents, is given in Figure 7. 
20 Ongoing response to quality assessment data about a service in ways that improve the processes 
by which services are provided to clients (source: ISQua).
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